Product Description
Cladribine is used to treat hairy cell leukemia (cancer of a certain type of white blood cell). Cladribine is in a class of medications known as purine analogs. It works by stopping or slowing the growth of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a693015.html)
Mechanisms of Action: TK Inhibitor, ADA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Merck KGaA
Company Location: GERMANY HRB 6164 I8
Company CEO: Belen Garijo
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Czech Republic, Denmark, France, Georgia, Germany, Greece, Ireland, Italy, Japan, Korea, Netherlands, Norway, Poland, South Korea, Spain, Sweden, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 11
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Charcot-Marie-Tooth Disease|Histiocytosis|Multiple Sclerosis|Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis, Relapsing-Remitting|Myasthenia Gravis
Phase 2: Acute Monocytic Leukemia|Acute Myeloid Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2024-512676-36-00 |
042011 | P3 |
Not yet recruiting |
Histiocytosis |
2025-12-30 |
2025-05-02 |
Treatments |
|
NCT06232655 |
23-0273.cc | P2 |
Recruiting |
Acute Myeloid Leukemia |
2026-10-01 |
2025-10-28 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT04121403 |
NOR-MS | P3 |
Completed |
Multiple Sclerosis |
2024-08-31 |
2024-12-18 |
Primary Endpoints |
|
NCT06504459 |
STUDY00026216 | P2 |
Recruiting |
Acute Myeloid Leukemia|Acute Monocytic Leukemia |
2027-10-11 |
12% |
2025-08-27 |
|
NCT06463587 |
MyClad | P3 |
Recruiting |
Myasthenia Gravis |
2028-05-19 |
19% |
2025-09-06 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments |
NCT04695080 |
ChariotMS | P3 |
Active, not recruiting |
Charcot-Marie-Tooth Disease|Multiple Sclerosis, Chronic Progressive |
2027-12-31 |
32% |
2025-09-09 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
NCT04047628 |
BEAT-MS | P3 |
Recruiting |
Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis, Relapsing-Remitting |
2026-10-01 |
41% |
2023-09-22 |
|
jRCT2031240175 |
jRCT2031240175 | P3 |
Not yet recruiting |
Myasthenia Gravis |
2031-02-28 |
|||
NCT06660368 |
MCC-23154 | P2 |
Recruiting |
Acute Myeloid Leukemia |
2027-11-01 |
12% |
2024-12-20 |
Primary Endpoints|Start Date|Treatments|Trial Status |
2023-507746-83-00 |
MS700568_0183 | P3 |
Recruiting |
Myasthenia Gravis |
2031-02-28 |
19% |
2025-05-02 |
Treatments |
NCT04086225 |
MS700568_0031 | P1 |
Recruiting |
Multiple Sclerosis |
2020-04-06 |
2019-09-12 |